MeSH tree: C23.550.291.500.483
Scientists at St. Jude Children's Research Hospital, the American Society for Hematology (ASH) and the Munich Leukemia Laboratory have developed a data-sharing platform that unites genomics, gene expression and clinical information ...
Apr 6, 2026
0
3
The U.S. Food and Drug Administration has approved an expanded indication for Eli Lilly's Jaypirca (pirtobrutinib), the first and only noncovalent Bruton tyrosine kinase (BTK) inhibitor for adults with relapsed or refractory ...
Dec 10, 2025
0
11
In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when compared with bendamustine ...
Dec 9, 2025
0
6
According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a single-agent treatment indefinitely or a combination treatment for a fixed period of time.
Dec 8, 2025
0
13
Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met the primary endpoint for non-inferiority in terms of overall response rate in the first head-to-head comparison with ibrutinib, a covalent BTK inhibitor. ...
Dec 8, 2025
0
5
Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and molecular differences between the two main subtypes of chronic lymphocytic leukemia, CLL. The findings, ...
Nov 18, 2025
0
23
Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia in the Western Hemisphere, affecting approximately 200,000 people in the United States.
Nov 6, 2025
0
20
A new tool developed by Weill Cornell Medicine and the University of Adelaide investigators has enhanced the ability to track multiple gene mutations while simultaneously recording gene activity in individual cancer cells. ...
Oct 10, 2025
0
48
At a memorial service in 2022, veteran Air Force Capt. Monte Watts bumped into a fellow former Minuteman III nuclear missile operator, who told him that she had non-Hodgkin lymphoma.
Oct 9, 2025
0
9
Researchers from King's have identified a new way to treat certain blood cancers using existing drugs, by turning a once-dismissed part of our DNA into a therapeutic target.
Sep 11, 2025
0
17
